Stereotactic Ablative Body Radiotherapy for Intermediate- or High-Risk Prostate Cancer.

Stereotactic Ablative Body Radiotherapy for Intermediate- or High-Risk Prostate Cancer. Cancer J. 2020 Jan/Feb;26(1):38-42 Authors: Loblaw A Abstract Stereotactic ablative radiotherapy (SABR) is a relatively novel form of high precision radiotherapy. For low- and intermediate risk patients, ultrahypofractionation (UHF - more than 5 Gy per day) has been compared to conventionally fractionated or moderately hypofractionated radiotherapy in two large randomized studies. A third smaller randomized study examined the question of the optimal frequency of treatments. The results of these studies will be reviewed. SABR for high risk prostate cancer has been shown to be feasible and is well tolerated with careful planning and setup techniques. However, there is currently insufficient data supporting its use for high-risk patients to offer SABR outside of a clinical trial. SABR costs less to the radiotherapydepartments and, the patient, as well as increasing system capacity. Therefore, it has the potential to be widely adopted in the next few years. PMID: 31977383 [PubMed - in process]
Source: Cancer Journal - Category: Cancer & Oncology Authors: Tags: Cancer J Source Type: research